Overdosage of letibotulinumtoxinA is likely to result in excessive neuromuscular weakness with a variety of associated symptoms. Patients should be monitored closely in the event of an overdose, and may require respiratory support if respiratory paralysis occurs.L42330
Symptoms of overdosage are not likely to be present immediately following injection, and patients should be medically supervised for several weeks for signs and symptoms of excessive muscle weakness or paralysis.L42330
The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s.A249920 The first aesthetic use of botulinum toxin was reported in 1989, when onabotulinumtoxinA (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial nerve damage.A249920 It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.A249920
LetibotulinumtoxinA is a type A botulinum neurotoxin produced from fermentation of Clostridium botulinum strain CBFC26.L42330 It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins.L42330 LetibotulinumtoxinA has been a market-leading cosmetic product in South Korea for a number of years and was subsequently approved in the European Union.L42335 It was approved for use in the treatment of glabellar lines in Canada in June 2022L42330,L42335 and in the US in March 2024.L50291,L50296
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Capreomycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Capreomycin. |
| Botulinum toxin type B | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Botulinum toxin type B. |
| Botulinum toxin type A | The risk or severity of neuromuscular blockade can be increased when Botulinum toxin type A is combined with Letibotulinumtoxina. |
| Cyclosporine | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Cyclosporine. |
| Doxycycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Doxycycline. |
| Lymecycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Lymecycline. |
| Piperacillin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Piperacillin. |
| Framycetin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Framycetin. |
| Clomocycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Clomocycline. |
| Quinine | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Quinine. |
| Vancomycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Vancomycin. |
| Tigecycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Tigecycline. |
| Oxytetracycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Oxytetracycline. |
| Chloroquine | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Chloroquine. |
| Demeclocycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Demeclocycline. |
| Magnesium sulfate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium sulfate. |
| Mecamylamine | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Mecamylamine. |
| Tobramycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Tobramycin. |
| Tetracycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Tetracycline. |
| Gentamicin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Gentamicin. |
| Colistin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Colistin. |
| Etacrynic acid | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Etacrynic acid. |
| Quinidine | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Quinidine. |
| Metacycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Metacycline. |
| Netilmicin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Netilmicin. |
| Neomycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Neomycin. |
| Minocycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Minocycline. |
| Procainamide | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Procainamide. |
| Streptomycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Streptomycin. |
| Colistimethate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Colistimethate. |
| Kanamycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Kanamycin. |
| Clindamycin | The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Letibotulinumtoxina. |
| Dantrolene | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Dantrolene. |
| Rolitetracycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Rolitetracycline. |
| Magnesium oxide | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium oxide. |
| Magnesium cation | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium cation. |
| Paromomycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Paromomycin. |
| Lincomycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Lincomycin. |
| Ribostamycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Ribostamycin. |
| Geneticin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Geneticin. |
| Apramycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Apramycin. |
| Gentamicin C1a | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Gentamicin C1a. |
| Neamine | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Neamine. |
| Arbekacin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Arbekacin. |
| Viomycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Viomycin. |
| Puromycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Puromycin. |
| Magnesium hydroxide | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium hydroxide. |
| Magnesium trisilicate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium trisilicate. |
| Magnesium chloride | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium chloride. |
| Magnesium acetate tetrahydrate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium acetate tetrahydrate. |
| Magnesium carbonate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium carbonate. |
| Magnesium citrate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium citrate. |
| Magnesium glycinate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium glycinate. |
| Magnesium Aluminum Silicate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium Aluminum Silicate. |
| Dihydrostreptomycin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Dihydrostreptomycin. |
| Hygromycin B | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Hygromycin B. |
| Sisomicin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Sisomicin. |
| Plazomicin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Plazomicin. |
| Magnesium silicate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium silicate. |
| Penimepicycline | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Penimepicycline. |
| Magnesium aspartate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium aspartate. |
| Isepamicin | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Isepamicin. |
| Magnesium gluconate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium gluconate. |
| Magnesium orotate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium orotate. |
| Magnesium phosphate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium phosphate. |
| Magnesium acetate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium acetate. |
| Magnesium stearate | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium stearate. |
| Digoxin | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Digoxin. |
| Acetyldigitoxin | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Deslanoside. |
| Ouabain | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Ouabain. |
| Digitoxin | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Digitoxin. |
| Oleandrin | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Oleandrin. |
| Cymarin | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Cymarin. |
| Proscillaridin | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Proscillaridin. |
| Metildigoxin | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Metildigoxin. |
| Lanatoside C | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Lanatoside C. |
| Gitoformate | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Gitoformate. |
| Acetyldigoxin | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Acetyldigoxin. |
| Peruvoside | The risk or severity of Cardiac Arrhythmia can be increased when Letibotulinumtoxina is combined with Peruvoside. |
| Phenytoin | The therapeutic efficacy of Letibotulinumtoxina can be decreased when used in combination with Phenytoin. |
| Fosphenytoin | The therapeutic efficacy of Letibotulinumtoxina can be decreased when used in combination with Fosphenytoin. |
| Flunisolide | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Flunisolide. |
| Fluorometholone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Fluorometholone. |
| Beclomethasone dipropionate | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Beclomethasone dipropionate. |
| Betamethasone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Betamethasone. |
| Desoximetasone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Desoximetasone. |
| Fluticasone propionate | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Fluocinolone acetonide. |
| Triamcinolone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Triamcinolone. |
| Prednisone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Prednisone. |
| Flumethasone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Flumethasone. |
| Fludrocortisone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Fludrocortisone. |
| Hydrocortisone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Hydrocortisone. |
| Mometasone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Mometasone. |
| Prednisolone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Prednisolone. |
| Methylprednisolone | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Methylprednisolone. |
| Clobetasol propionate | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Clobetasol propionate. |
| Fluocinonide | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Fluocinonide. |
| Trilostane | The risk or severity of myopathy and weakness can be increased when Letibotulinumtoxina is combined with Trilostane. |